Pancreatic cancer is a highly malignant digestive tract malignant tumor, and stage IV indicates that it is already advanced and more serious. Pancreatic cancer is a kind of digestive tract malignant tumor with insidious onset, rapid progression, and extremely poor therapeutic effect and prognosis. Pancreatic cancer staging follows AJCC-TNM staging, which comprehensively evaluates the patient’s primary foci, regional lymph nodes and distant metastases. Among them, stage IV refers to patients with combined distant metastases. Patients with pancreatic cancer combined with distant metastases indicate that the disease has reached an advanced stage and is no longer amenable to surgical resection. Usually, they can only receive treatment options such as radiotherapy to control the progression of the disease, and stent placement and drainage to improve symptoms. Patients with advanced pancreatic cancer have a very poor prognosis and a short survival period. Some studies claim that the 1-, 2-, and 3-year survival rates after diagnosis of pancreatic cancer are 21.5%, 6.0%, and 4.0%, respectively, and the overall median survival is only 5.5 months, while the prognosis for patients with advanced pancreatic cancer is even worse. In addition, patients with advanced pancreatic cancer often have serious clinical symptoms and comorbidities, such as severe nausea, vomiting, inability to eat, jaundice, cachexia, severe pain and other symptoms. It is recommended that patients should go to regular hospitals in time when they are not feeling well and should cooperate with doctors for active treatment.